The European Commission has granted orphan drug designation to Alexion Pharmaceuticals‘ Soliris® (eculizumab) for the treatment of patients with myasthenia gravis, a rare, debilitating neurologic disorder caused by uncontrolled complement activation … more

A marketing authorization application for asfotase alfa, Alexion‘s investigational, first-in-class targeted enzyme replacement therapy for the treatment of hypophosphatasia, has been validated and granted accelerated assessment by the European Medicines Agency … more

The Dutch subsidiary of Durata Therapeutics has entered into a license and supply agreement with Angelini, an international group leader in the pharmaceutical and mass-market sectors, to commercialize dalbavancin in 36 countries … more